New pill targets heart risk by lowering inflammation – first human trial begins
NCT ID NCT07119125
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called MRT-8102 for the first time in humans. It includes healthy volunteers and people with high inflammation (elevated CRP) who are at risk for heart problems. The goal is to check the drug's safety and find the right dose for future studies. Participants receive either the drug or a placebo by mouth for up to 28 days.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ELEVATED CRP are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Pharmacology of Miami, LLC
Miami, Florida, 33172, United States
-
Endeavor Clinical Trials
San Antonio, Texas, 78240, United States
-
ICON Clinical Research
Lenexa, Kansas, 66219, United States
-
QPS
Springfield, Missouri, 65807, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults